Development and translation of novel therapeutics targeting tumor-associated macrophages.
Cancer
Therapy development
Tumor microenvironment
Tumor-associated macrophages
Journal
Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
06
07
2018
revised:
25
09
2018
accepted:
03
10
2018
pubmed:
22
11
2018
medline:
26
6
2020
entrez:
22
11
2018
Statut:
ppublish
Résumé
Tumor-associated macrophages (TAMs) regulate an array of tumor functions and have critical roles in both the progression and the eradication of cancer. Numerous therapies targeting TAMs are under development in cancer and many have demonstrated success at the preclinical and clinical levels. Most of these therapies fall within 3 main categories: systemic depletion of TAMs, inhibition of TAM recruitment and polarization, and promoting the antitumor functions of TAMs. In this article, the rationale behind these various therapies and approaches is reviewed along with supporting preclinical and clinical data.
Identifiants
pubmed: 30458979
pii: S1078-1439(18)30392-2
doi: 10.1016/j.urolonc.2018.10.010
pmc: PMC6525088
mid: NIHMS1509582
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
556-562Subventions
Organisme : NIA NIH HHS
ID : T32 AG000213
Pays : United States
Informations de copyright
Copyright © 2018 Elsevier Inc. All rights reserved.
Références
Neoplasia. 2007 Jul;9(7):556-62
pubmed: 17710158
Cancer Res. 2010 Mar 15;70(6):2235-44
pubmed: 20215499
Cancer Cell. 2009 Aug 4;16(2):91-102
pubmed: 19647220
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416
pubmed: 28117416
Cancer Res. 2010 Sep 1;70(17):6945-56
pubmed: 20699369
Int J Cancer. 1992 Apr 22;51(1):42-6
pubmed: 1563843
Breast Cancer Res Treat. 2014 Nov;148(2):291-302
pubmed: 25311112
Science. 2011 Mar 25;331(6024):1612-6
pubmed: 21436454
Neoplasia. 2009 Nov;11(11):1235-42
pubmed: 19881959
Cancer Res. 2014 Sep 15;74(18):5057-69
pubmed: 25082815
Nature. 2010 Jun 10;465(7299):697-9
pubmed: 20535192
Cancers (Basel). 2014 Aug 13;6(3):1670-90
pubmed: 25125485
J Clin Oncol. 1996 Feb;14(2):343-50
pubmed: 8636742
Proc Natl Acad Sci U S A. 2012 Feb 7;109(6):2066-71
pubmed: 22308357
Lancet Oncol. 2016 May;17(5):651-62
pubmed: 27055731
Int J Cancer. 2009 Jul 15;125(2):367-73
pubmed: 19378341
Lab Chip. 2014 Jan 7;14(1):24-31
pubmed: 24190548
Cancer Immunol Res. 2013 Oct;1(4):256-68
pubmed: 24777853
Cancer Cell. 2013 Feb 11;23(2):249-62
pubmed: 23410977
J Transl Med. 2009 Jun 19;7:49
pubmed: 19545375
Sci Rep. 2015 Oct 27;5:15651
pubmed: 26503803
Clin Cancer Res. 2013 Nov 15;19(22):6286-95
pubmed: 23983255
Cancer Discov. 2011 Jun;1(1):54-67
pubmed: 22039576
Annu Rev Immunol. 2010;28:157-83
pubmed: 19968561
Cancer Cell. 2013 Dec 9;24(6):695-709
pubmed: 24332039
Nat Med. 2013 Oct;19(10):1264-72
pubmed: 24056773
Neuro Oncol. 2016 Jun;18(6):797-806
pubmed: 26538619
Science. 2013 Feb 22;339(6122):971-5
pubmed: 23430657
Mol Oncol. 2014 Oct;8(7):1231-9
pubmed: 24816187
Cancer Chemother Pharmacol. 2013 Apr;71(4):1041-50
pubmed: 23385782
PLoS One. 2012;7(12):e50946
pubmed: 23284651
J Cell Biochem. 2009 May 1;107(1):58-64
pubmed: 19259948
Oncogene. 2014 Jul 17;33(29):3812-9
pubmed: 23995783
N Engl J Med. 2015 Jul 30;373(5):428-37
pubmed: 26222558
Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):14016-21
pubmed: 19666525
Cancer Res. 2010 Feb 15;70(4):1534-43
pubmed: 20145121
Cancer Res. 2014 Jan 1;74(1):153-161
pubmed: 24247719
Sci Rep. 2015 Sep 09;5:13855
pubmed: 26349896
Cancer Res. 2003 Dec 1;63(23):8360-5
pubmed: 14678997
Eur J Immunol. 1997 Oct;27(10):2626-33
pubmed: 9368619
J Immunother. 2014 Jun;37(5):293-303
pubmed: 24810641
Br J Cancer. 2006 Aug 7;95(3):272-81
pubmed: 16832418
Nat Immunol. 2010 Oct;11(10):889-96
pubmed: 20856220
Cancer Res. 2015 Mar 15;75(6):950-62
pubmed: 25736687
Nat Rev Cancer. 2008 Aug;8(8):618-31
pubmed: 18633355
Cancer Res. 2013 May 1;73(9):2782-94
pubmed: 23418320
Cancer Cell. 2014 Jun 16;25(6):846-59
pubmed: 24898549